Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05023889 · ClinicalTrials.gov registry record · Early Phase 1
Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy
A Early Phase 1 study of Transthyretin Amyloidosis and Polyneuropathies, sponsored by Austin Neuromuscular Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT05023889 is a Early Phase 1 study of Transthyretin Amyloidosis and Polyneuropathies that is active but no longer recruiting, run by Austin Neuromuscular Center. The registered enrollment target is 10 participants, below the 1,257-participant average among 8 other Transthyretin Amyloidosis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05023889, a Early Phase 1 study of Transthyretin Amyloidosis and Polyneuropathies, is active but no longer recruiting, sponsored by Austin Neuromuscular Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the efficacy and safety of patisiran in patients with wtATTR amyloidosis and symptomatic polyneuropathy by evaluating the effect on neurologic impairment and quality of life.
Conditions Studied
Interventions
- DRUG patisiran
Study Locations (1)
Texas
- Austin Neuromuscler Center/National Neuromuscular Research Institute - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-08-03 |
| Est. Completion | 2026-02-25 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05023889
The ClinicalTrials.gov registry entry for NCT05023889 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,257-participant average among 8 other Transthyretin Amyloidosis trials with a reported enrollment target (99% lower). The listed sponsor is Austin Neuromuscular Center, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Transthyretin Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which patisiran is the first listed.
NCT05023889 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05023889 about?
NCT05023889 is a clinical study titled "Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy". To evaluate the efficacy and safety of patisiran in patients with wtATTR amyloidosis and symptomatic polyneuropathy by evaluating the effect on neurologic impairment and quality of life.
What is the current status of trial NCT05023889?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2022-08-03. Estimated completion is 2026-02-25.
What conditions does trial NCT05023889 study?
This clinical trial studies the following conditions: Transthyretin Amyloidosis, Polyneuropathies, Wild Type ATTR Amyloidosis, Wild-Type Transthyretin-Related (ATTR)Amyloidosis, Wild-Type Transthyretin Cardiac Amyloidosis.
What interventions are being tested in trial NCT05023889?
The interventions under investigation include: patisiran (DRUG).
Who is sponsoring clinical trial NCT05023889?
This trial is sponsored by Austin Neuromuscular Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05023889 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transthyretin Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis
COMPLETED · Early Phase 1
-
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
RECRUITING · Phase 2
-
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
RECRUITING
-
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
RECRUITING · Phase 3
-
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
RECRUITING · NA
-
Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.